“The award means a lot for us as his parents … We (parents) think it is very significant, we are awed by it. We are humbled as we didn’t know his reach was so far. … the people he influenced and who love him. He was only a young man,” James told The Gleaner at yesterday’s function. Meanwhile, there will be some other new features to the tournament this year. The draw for the first round of games will take place at the National Indoor Sports Centre on October 19. Unlike last season when all the first-round matches were played on the same day, this season, the opening round of matches will be contested over two days (Friday and Saturday) at two venues, Sabina Park (Kingston) and Catherine Hall (Montego Bay), starting at 5 p.m. and 7 p.m. There will also be a Super Cup anthem, which will be played prior to the start of every game. Each team qualifying for the Super Cup is guaranteed $25,000 for making the first round. The amount doubles after each round. The quarter-final teams will receive $50,000, semi-finalists $100,000, and the finalists $200,000 each. MVP and Golden Boot winners will receive trophies and $100,000 towards their personal development. The winning school is set to take home a prize purse of $1 million. email@example.com A new most valuable player (MVP) award will be handed out for this year’s FLOW Super Cup, which kicks off on October 21. The award will be called the Dominic James MVP Award in memory of the former St George’s College captain who collapsed during a Manning Cup match on September 20 and died after being rushed to hospital. FLOW’s vice-president for marketing and television Carlo Redwood described the St George’s captain as a “leader, very dependable, disciplined and humble” at yesterday’s launch of the 2016 Super Cup at the Spanish Court Hotel in New Kingston. “We have decided to introduce a new award this year, and the award will pay recognition to young Dominic James in a special way. He is the only player to have won both Super Cup trophies, first with Jamaica College and St George’s College,” Redwood stated. A moment’s silence was also observed in memory of the player. Meanwhile, Dominic’s father, David, said the family was in ‘awe’, but he thought his son deserved to have the award named in his honour. HUMBLING EXPERIENCE
Cancer treatments that harness the body’s immune system to wipe out tumors have begun paying off for some patients for whom all other therapies have failed. Now, a small clinical study has found support for a newcomer on the cancer immunotherapy front. Injected with a vaccine designed to match specific mutations in their tumors, three patients with advanced melanoma had a strong immune response and in two their tumors shrunk or stabilized, at least temporarily. Although the study was mainly meant to test safety, the results suggest it holds promise for stopping tumors from growing.“There’s a lot of excitement about this approach,” says oncologist and cancer immunologist Craig Slingluff of the University of Virginia in Charlottesville, who was not involved with the study.Vaccines for infectious diseases typically deliver into the body bits of protein or other material from a virus or bacterium that trigger the immune system to defend against the invading pathogen. With cancer, the similar idea is to vaccinate a patient with immune-stimulating molecules, known as antigens, found only on tumor cells, so that the person’s immune system ends up attacking the tumor. But cancer vaccines have a poor record of success. That’s because most of the tumor antigens tested also appear in small amounts on healthy cells, and the immune system has mechanisms that make it tolerate, or ignore, these familiar antigens.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)Scientists have their eye on a more promising kind of tumor antigen: those that result from the mutations that riddle a tumor’s DNA, thanks to the chaos cancer causes to a genome. Some of these mutations do not appear in genes that drive cancer growth, but instead code for novel peptides—short proteins—that may act as antigens on the surface of tumor cells. Because these so-called neoantigens are completely foreign to the body, they could in theory make a cancer vaccine.Devising a neoantigen cancer vaccine requires sequencing a lot of tumor DNA, which wasn’t feasible or affordable until recently. But now that DNA sequencing costs have dropped and speeds increased, researchers at Washington University in St. Louis have begun exploring neoantigen cancer vaccines for melanoma, a tumor in which the sun’s ultraviolet light that sparks cancer-causing mutations also creates hundreds of additional mutations that are likely to include many coding for neoantigens.Human immunologist Beatriz Carreno, trial leader Gerald Linette, and collaborators recently studied three melanoma patients who had surgery to remove their tumors, but who had cancer cells that had spread to their lymph nodes, making tumors likely to recur. The researchers sequenced the exome, or protein-coding DNA, of each patient’s original melanoma tumor and compared it with the exome of their other cells to identify dozens of mutations coding for newly created peptides that might act as neoantigens. (Not all peptides made by a cell get displayed on its surface.) They analyzed the possible neoantigens’ structures and did lab tests to predict which are actually made by the cell and get displayed on its surface, then homed in on those most likely to trigger an immune response. For each melanoma patient they chose seven neoantigens unique to that person’s tumor.After taking blood from each patient and harvesting from it immune sentinels called dendritic cells, the researchers then mixed each patient’s set of neoantigens with these white blood cells so that they would display the peptides to other immune cells. The team used the neoantigen-coated dendritic cells to make personalized neoantigen vaccines that were infused into the patients three times over about 4 months.Carreno and collaborators found that a key measure of vaccine response, the number of immune system T cells specific to the neoantigens in each patient, rose in the patients’ blood, along with an increase in the diversity of these T cells. These neoantigen-specific T cells could also kill cultured melanoma cells expressing the same neoantigens, the team reports online today in Science.In one patient, metastatic tumors in the woman’s lungs shrank, then regrew, but are now stable after 8 months; the second person’s tumor remnants have also been stable for 9 months. A third patient who had received an immunotherapy drug after surgery that put his cancer in remission remains cancer-free. However, the trial was designed primarily to confirm the safety of the vaccine and immune response, not to test its effectiveness, and because the patients received other treatments, it is not possible to say whether the vaccine helped: “I would be speculating if I said that the vaccine had any benefit to the patients,” Linette says.But the fact that the study found “a pretty high magnitude of immune response,” combined with recent reports that a different neoantigen vaccine can fight cancer in mice, suggests the idea is “promising,” Slingluff says.Such a vaccine, which should be less toxic than chemotherapy, might be used to prevent cancer from recurring after surgery. It might also be combined with other immunotherapy drugs known as checkpoint inhibitors that seem to work best for cancers such as lung and melanoma in which tumors have many mutations. “The high anticipation is whether the one-two punch with checkpoint inhibition would work,” says Roger Lo, a melanoma researcher at the University of California, Los Angeles.
It’s a warm July day in Girdwood, but after a 10-minute helicopter ride into the Chugach Mountains to Eagle Glacier, it starts to look and feel a bit like winter. The temperature drops, and snow blankets the ground. About two dozen women—most from Alaska Pacific University’s cross country ski team—take advantage of the summertime snow during a week-long training camp.Download AudioThe athletes workout five hours a day, and spend their down time in a rustic building precariously perched beside a 5,000 foot cliff. Olympian Kikkan Randall has been coming to the trainings for 14 years, and says they’ve helped her become one of the world’s top speed skiers.“I’ve always been really proud of Eagle Glacier and the opportunities we have here,” she says. “We can ski twice a day, and we can do so at a moderate altitude where we don’t have to modify our training intensities, so it’s pretty unique.”While snow is a constant, relatively warm summer temperatures create less-than-ideal skiing conditions on the glacier. As the athletes trudge up a steep hill on the 10 kilometer track, they struggle to push through the slushy snow. But Erik Flora says the tough environment has its perks.“Every time the Olympics come up people pray for nice weather, but the trail always turns to a mess,” he says. “You have rain, sleet, soft snow and that’s the magic of Eagle Glacier because as you can see in the course here it’s not easy…. We have a term for it: championship weather.”APU skiers aren’t the only ones benefiting from the weeklong training. Each year at least one international athlete travels to Eagle glacier. Two years ago Aino-Kaisa Saarinen came from Finland and quickly befriended APU skier and Olympian Holly Brooks. The two reunited at the Sochi Olympics last winter where Saarinen took home two silver medals.“We ran into Aino Kaisa and she stopped us and she started crying and said I want to thank you girls, because I think spending time in Alaska and spending time with you really helped me and my team earn this medal,” Brooks recalls. “Of course we wished that the U.S. had been able to bring home that medal, but that was really a priceless moment for us.”This summer Norway’s Celine Brun-Lie traveled 4,000 miles to train on Eagle Glacier. Since thereare no places to ski in the summer in Norway, Brun-Lie says she’s having a blast in Alaska. And while she recognizes that many of the women she’s skiing with will be fierce competitors on the World Cup circuit come winter, right now she’s just trying to learn as much as she can.“I can teach Kikkan [Randall] something, she can teach me something, and then in the winter maybe I beat her because of what she taught me, or she beats me because I told her something,” Brun-Lie says. “But I think that’s the way it should work, and that’s the fun thing about sports.”The women’s training session ends Sunday, and APU’s men’s team will be on the glacier at the end of July.